SCHEMBL360971

SCHEMBL360971

CNC(=O)c1ccc(OCc2nn(-c3cnn(C)c3)ccc2=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.41
PLK1 P53350 3/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
AXL P30530 1/20 0.38
TYRO3 Q06418 1/20 0.38
MERTK Q12866 1/20 0.38
FGFR1 P11362 2/20 0.37
FGFR3 P22607 2/20 0.37
MET P08581 1/20 0.37
RAB9A P51151 1/20 0.37
NTRK1 P04629 1/20 0.36
PDGFRB P09619 1/20 0.36
KIT P10721 1/20 0.36
FLT3 P36888 1/20 0.36
CCNC P24863 2/20 0.36
CDK8 P49336 2/20 0.36
RIPK2 O43353 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360085 0.88 PARP10 (0.43) TBXAS1
SCHEMBL12503516 0.87 DGAT1 (0.39) METRAB9ANTRK1KITSMN1; SMN2
SCHEMBL371168 0.87 RAB9A (0.38) AXLMERTKRAB9ARIPK2MAPT
SCHEMBL360220 0.85 TBXAS1 (0.41) TBXAS1RAB9AHPGDTSHRHTT
SCHEMBL14930551 0.84 ALDH1A1 (0.38) RAB9AHPGDHTTSMN1; SMN2
SCHEMBL12503425 0.84 MEN1 (0.40) RAB9AHTTSMN1; SMN2MAPT
SCHEMBL359456 0.83 FGFR1 (0.36) AXLMERTKFGFR1FGFR3MET
SCHEMBL10283805 0.81 NPC1 (0.32) FGFR1FGFR3RAB9ASMN1; SMN2
SCHEMBL14926941 0.81 MAPT (0.42) AXLFGFR1METRAB9ANTRK1
SCHEMBL10283775 0.81 TP53 (0.38) RAB9ATSHRSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP claimed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US claimed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO claimed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET TBXAS1 1634/4885PLK1 302/4885MRGPRX4 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.